Other Information
−Removed: During the three months ended September 30, 2025, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408 of Regulation S-K).
−Removed: 2.1 Agreement and Plan of Merger, among Halozyme Therapeutics, Inc., Erraid Merger Sub Inc., Elektrofi, Inc.
−Removed: and Shareholder Representative Services LLC, solely in its capacity as the representative of the securityholders as set forth in the Merger Agreement dated as of September 30, 2025 (filed as Exhibit 2.1 to the C ompany ’ s F orm 8-K filed October 3, 2025 and incorporated herein by refer ence)
+Added: During the three months ended March 31, 2026, the following director adopted a Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408 of Regulation S-K) as noted in the table below.
+Added: Trading Arrangement
+Added: Name and Title
+Added: Non-Rule 10b5-1**
+Added: Total Shares To Be Sold
+Added: Expiration Date
+Added: Mahesh Krishnan
+Added: 7,304 6/1/2027
+Added: * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
+Added: ** Non-Rule 10b5-1 trading arrangement as defined in Item 408(c) of Regulation S-K under the Exchange Act
3.1 Amended and Restated Certificate of Incorporation of Halozyme Therapeutics, Inc.
(filed as Exhibit 3.1 to the Company’s Form 8-K filed April 26, 2024 and incorporated herein by reference)
−Removed: 3.2 The Company Bylaws, as amended (filed as Exhibit 3.1 to the Company’s Form 8-K filed December 10, 2021 and incorporated herein by reference)
+Added: 3.2 The Company Bylaws, as amended (filed as Exhibit 3.1 to the Company’s Form 8-K filed April 24, 2026 and incorporated herein by reference)
4.1 Indenture, dated March 1, 2021, between Halozyme Therapeutics, Inc.
6 unchanged sentences
and The Bank of New York Mellon Trust Company, N.A., as trustee (included within Exhibit 4.3) ( filed as Exhibit 4.2 to the Company’s Form 8-K filed August 18, 2022 and incorporated herein by reference )
+Added: 4.5 2031 Convertible Notes I ndenture, dated November 12, 2025, between Halozyme Ther apeutics, Inc.
+Added: and The Bank of New York Mellon Trust Company , N.A., as tr ustee (filed as Exhibit 4.1 to the Company ’ s Form 8-K filed November 12, 2025 and incorporated herein by reference)
+Added: 4.6 F orm of 0% Convertible Senior Notes due 2031 (included with in Exhibit 4.5) (filed as Exhibit 4.2 to the C ompany ’ s Form 8-K filed November 12, 2025 and incorporated herein by ref erence)
+Added: 4.7 203 2 Convertible Notes Indenture, dated November 12, 2025, between Halozyme Therapeutics, Inc.
+Added: and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.
+Added: 3 to the Company’s Form 8-K filed November 12, 2025 and incorporated herein by reference)
+Added: 4.8 Form of 0 .875 % Convertible Senior Notes due 203 2 (included within Exhibit 4.
+Added: 7 ) (filed as Exhibit 4.
+Added: 4 to the Company’s Form 8-K filed November 12, 2025 and incorporated herein by reference)
31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended (filed herewith)
11 unchanged sentences
Halozyme Therapeutics, Inc.
−Removed: November 3, 2025 By:
+Added: May 11, 2026 By:
Ch.B., M.R.C.P.
2 unchanged sentences
(Principal Executive Officer)
−Removed: November 3, 2025 By:
−Removed: /s/ Nicole LaBrosse
−Removed: Nicole LaBrosse
−Removed: Senior Vice President and Chief Financial Officer
+Added: May 11, 2026 By:
+Added: /s/ David Ramsay
+Added: Interim Chief Financial Officer
(Principal Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.